188 related articles for article (PubMed ID: 36472984)
1. Association between antidementia medication use and mortality in people diagnosed with dementia with Lewy bodies in the UK: A retrospective cohort study.
Chen S; Price AC; Cardinal RN; Moylett S; Kershenbaum AD; Fitzgerald J; Mueller C; Stewart R; O'Brien JT
PLoS Med; 2022 Dec; 19(12):e1004124. PubMed ID: 36472984
[TBL] [Abstract][Full Text] [Related]
2. Are antidementia drugs associated with reduced mortality after a hospital emergency admission in the population with dementia aged 65 years and older?
Hapca S; Burton JK; Cvoro V; Reynish E; Donnan PT
Alzheimers Dement (N Y); 2019; 5():431-440. PubMed ID: 31517030
[TBL] [Abstract][Full Text] [Related]
3. Mortality in dementia with Lewy bodies compared with Alzheimer's dementia: a retrospective naturalistic cohort study.
Price A; Farooq R; Yuan JM; Menon VB; Cardinal RN; O'Brien JT
BMJ Open; 2017 Nov; 7(11):e017504. PubMed ID: 29101136
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Prescription and Long-Term Utilization of Antidementia Drugs Among Patients with Alzheimer's Disease in Spain: A Cohort Study Using the Registry of Dementias of Girona.
Calvó-Perxas L; Turró-Garriga O; Vilalta-Franch J; Lozano-Gallego M; de Eugenio R; Márquez F; Carmona O; Gich J; Manzano A; Viñas M; Roig AM; Garre-Olmo J;
Drugs Aging; 2017 Apr; 34(4):303-310. PubMed ID: 28258538
[TBL] [Abstract][Full Text] [Related]
5. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
8. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.
Aarsland D; Ballard C; Walker Z; Bostrom F; Alves G; Kossakowski K; Leroi I; Pozo-Rodriguez F; Minthon L; Londos E
Lancet Neurol; 2009 Jul; 8(7):613-8. PubMed ID: 19520613
[TBL] [Abstract][Full Text] [Related]
9. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
[TBL] [Abstract][Full Text] [Related]
10. Association between lithium use and the incidence of dementia and its subtypes: A retrospective cohort study.
Chen S; Underwood BR; Jones PB; Lewis JR; Cardinal RN
PLoS Med; 2022 Mar; 19(3):e1003941. PubMed ID: 35298477
[TBL] [Abstract][Full Text] [Related]
11. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
12. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Parsons C; Lim WY; Loy C; McGuinness B; Passmore P; Ward SA; Hughes C
Cochrane Database Syst Rev; 2021 Feb; 2(2):CD009081. PubMed ID: 35608903
[TBL] [Abstract][Full Text] [Related]
14. Asthma and Chronic Obstructive Pulmonary Disease as a Comorbidity and Association with the Choice of Antidementia Medication Among Persons with Alzheimer's Disease.
Lampela P; Tolppanen AM; Koponen M; Tanskanen A; Tiihonen J; Hartikainen S; Taipale H
J Alzheimers Dis; 2020; 73(3):1243-1251. PubMed ID: 31929157
[TBL] [Abstract][Full Text] [Related]
15. Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies.
Moylett S; Price A; Cardinal RN; Aarsland D; Mueller C; Stewart R; O'Brien JT
J Alzheimers Dis; 2019; 67(3):995-1005. PubMed ID: 30776008
[TBL] [Abstract][Full Text] [Related]
16. Associations of acetylcholinesterase inhibitor treatment with reduced mortality in Alzheimer's disease: a retrospective survival analysis.
Mueller C; Perera G; Hayes RD; Shetty H; Stewart R
Age Ageing; 2018 Jan; 47(1):88-94. PubMed ID: 28655175
[TBL] [Abstract][Full Text] [Related]
17. The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer's Dementia: A Double-Blind Randomized Placebo-Controlled Trial.
Youn H; Lee KJ; Kim SG; Cho SJ; Kim WJ; Lee WJ; Hwang JY; Han C; Shin C; Jung HY
Psychiatry Investig; 2021 Mar; 18(3):233-240. PubMed ID: 33685036
[TBL] [Abstract][Full Text] [Related]
18. Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case-control study.
Tamimi I; Nicolau B; Eimar H; Arekunnath Madathil S; Kezouh A; Karp I; Tamimi F
Osteoporos Int; 2018 Apr; 29(4):849-857. PubMed ID: 29264626
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
